NASDAQ · IVA
Healthcare · Biotechnology
$4.03
Down-$0.16 (-3.87%)
Updated Nov 4, 2026, 9:00 PM
SID Score
4.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · IVA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
IVA closed at $4.03 after 21 trading sessions, up 16.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $3.80 | $4.165 | $3.78 | $4.03 | 4.08M |
| Nov 2, 2026 | $3.62 | $3.9899 | $3.551 | $3.83 | 3.25M |
| Oct 30, 2026 | $3.69 | $3.76 | $3.585 | $3.65 | 1.73M |
| Oct 29, 2026 | $3.75 | $3.8599 | $3.68 | $3.73 | 1.44M |
| Oct 28, 2026 | $3.69 | $3.77 | $3.65 | $3.71 | 946.95K |
| Oct 27, 2026 | $3.77 | $3.855 | $3.625 | $3.685 | 1.78M |
| Oct 26, 2026 | $3.67 | $3.865 | $3.64 | $3.66 | 3.33M |
| Oct 23, 2026 | $3.53 | $3.76 | $3.47 | $3.71 | 4.71M |
| Oct 22, 2026 | $3.40 | $3.63 | $3.395 | $3.60 | 2.4M |
| Oct 21, 2026 | $3.25 | $3.73 | $3.25 | $3.55 | 5.25M |
| Oct 20, 2026 | $3.00 | $3.3588 | $3.00 | $3.26 | 2.64M |
| Oct 19, 2026 | $3.00 | $3.09 | $2.95 | $2.98 | 3.95M |
| Oct 16, 2026 | $3.14 | $3.14 | $2.905 | $2.94 | 4.85M |
| Oct 15, 2026 | $2.975 | $3.18 | $2.935 | $3.11 | 2.91M |
| Oct 14, 2026 | $2.87 | $2.96 | $2.82 | $2.87 | 3.15M |
| Oct 13, 2026 | $3.02 | $3.035 | $2.87 | $2.87 | 2.51M |
| Oct 12, 2026 | $3.25 | $3.27 | $3.10 | $3.12 | 3.27M |
| Oct 9, 2026 | $3.35 | $3.35 | $3.15 | $3.16 | 2.79M |
| Oct 8, 2026 | $3.34 | $3.39 | $3.16 | $3.32 | 2.17M |
| Oct 7, 2026 | $3.46 | $3.46 | $3.275 | $3.365 | 2.4M |
| Oct 6, 2026 | $3.53 | $3.54 | $3.285 | $3.46 | 2.2M |
The latest Smart Investors Daily articles mentioning IVA.
Company
Market Activity
Research & News
IVA research
Company profile and research snapshot.
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 16, 2026 | PIPER SANDLER COMPANIES | Overweight | — |
| Sep 15, 2026 | GUGGENHEIM SECURITIES LLC | Buy | — |
| Sep 3, 2026 | KBC SECURITIES | Buy | — |
| Aug 13, 2026 | CANTOR FITZGERALD | Overweight | — |
| Aug 1, 2026 | TD COWEN | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Oct 14, 2026
Inventiva's substantial MASH market opportunity hinges on clinical differentiation and adoption among currently untreated patients. Read more on IVA stock here.
Yahoo · Oct 10, 2026
Inventiva, Larimar Therapeutics, and Ascentage Pharma face key drug-development milestones, with analysts assigning Buy ratings and triple-digit upside price targets to all three biotech stocks.
Yahoo · Oct 6, 2026
Preclinical data showed that balanced PPARα, PPARδ and PPARγ activation by lanifibranor affects complementary pathways across multiple hepatic cell populations involved in fibrosis in MASH pathogenesisPreclinical data and Phase 2b clinical results showed lanifibranor improved liver sinusoidal endothelial cell alterations and was associated with changes in intrahepatic vascular abnormalities across multiple stages of diseaseAnalysis of plasma cell-free DNA (cfDNA) identified coordinated epigeneti
Yahoo · Oct 4, 2026
Inventiva (NASDAQ:IVA) presents a high-stakes clinical binary play, anchored by a cash runway that extends only into Q2 2027 against a €69.5 million first-half net loss. With no commercial products generating revenue, its long-term fundamental story hinges entirely on de-risking its lead asset to capture a portion of an estimated $15 billion MASH market by […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning IVA.
